SGLT2i and Incretin and CRTd.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT03282136

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03282136
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03282136. Randomized; single masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2024-09-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2i and Incretin and CRTd.
Condition
Type 2 Diabetes Mellitus
Condition
Heart Failure
Intervention (Drug)
Incretin Effect
Intervention (Device)
Cardiac Resynchronization therapy defibrillator device
Intervention (Drug)
SGLT-2 inhibitor
Lead sponsor
University of Campania Luigi Vanvitelli (class: other)

Record details

Record id
cardio:ct-nct03282136
Content hash
25aab018494c296002f5fd7db043a04558657967fcb49ea9389c045e1ea550b3